• 1
    Hagen EC, Andrassy K, Csernok E et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Meth 1996; 196:115.
  • 2
    Savige J, Gillis D, Benson E et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111:50713.
  • 3
    Trevisin M, Neeson P, Savige J. The binding of proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) varies in different ELISAs. J Clin Pathol 2004; 57:3038.
  • 4
    Csernok E, Holle J, Hellmich B et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxf) 2004; 43:17480.
  • 5
    Savige JA, Chang L, Horn S et al. Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals. Autoimmunity 1994; 18:20511.
  • 6
    Wiik A, Van Der Woude F. Anti-neutrophil cytoplasmic antibodies (ANCA): a historic review. APMIS Suppl 1989; 6:7.
  • 7
    Plow EF. Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway. J Clin Invest 1982; 69:56472.
  • 8
    Bladbjerg EM, Overgaard K, Gram J et al. The protein concentration of blood coagulation factor VII can be measured equally well in plasma and serum. Scand J Clin Lab Invest 1995; 55:26771.
  • 9
    Bereczki D, Nagy E, Pal A et al. Should soluble CD40 ligand be measured from serum or plasma samples? Arterioscler Thromb Vasc Biol 2003; 23:112930; author reply 1130–1.
  • 10
    Jung K. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? J Neuroimmunol 2005; 162:12.
  • 11
    The WGET, Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:35161.
  • 12
    The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003; 48:2299309.
  • 13
    Russell KA, Wiegert E, Schroeder DR et al. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103:196203.
  • 14
    Sun J, Fass DN, Hudson JA et al. Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes. J Immunol Meth 1998; 211:11123.
  • 15
    Sun J, Fass DN, Viss MA et al. A proportion of proteinase 3-specific anti-neutrophil cytoplasmic antibodies only react with proteinase 3 after cleavage of its N-terminal activation dipeptide. Clin Exp Immunol 1998; 114:3206.
  • 16
    Lee AS, Finkielman JD, Peikert T et al. A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. J Immunol Meth 2005; 307:6272.
  • 17
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:30710.
  • 18
    Dolman KM, Jager A, Sonnenberg A et al. Proteolysis of classic anti-neutrophil cytoplasmic autoantibodies (C-ANCA) by neutrophil proteinase 3. Clin Exp Immunol 1995; 101:812.
  • 19
    Baslund B, Petersen J, Permin H et al. Measurements of proteinase 3 and its complexes with a1-proteinase inhibitor and anti-neutrophil cytoplasm antibodies (ANCA) in plasma. J Immunol Meth 1994; 175:21525.
  • 20
    Baslund B, Segelmark M, Wiik A et al. Screening for anti-neutrophil cytoplasmic antibodies (ANCA): is indirect immunofluorescence the method of choice? Clin Exp Immunol 1995; 99:48692.